Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.48−0.52 (-1.26%)
Close on Nov 13, 2026Market cap $3.92BP/E –Yield –
Xenon Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Xenon Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$463.00M. For fiscal 2025 it was -$370.53M. The highest annual figure on record is $11.84M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$370.53M | – |
| FY2024 | Dec 31, 2024 | -$276.74M | – |
| FY2023 | Dec 31, 2023 | -$211.99M | – |
| FY2022 | Dec 31, 2022 | -$127.74M | – |
| FY2021 | Dec 31, 2021 | -$78.09M | – |
| FY2020 | Dec 31, 2020 | -$30.66M | – |
| FY2019 | Dec 31, 2019 | -$42.39M | – |
| FY2018 | Dec 31, 2018 | -$37.45M | – |
| FY2017 | Dec 31, 2017 | -$31.93M | – |
| FY2016 | Dec 31, 2016 | -$23.95M | – |
| FY2015 | Dec 31, 2015 | -$8.32M | -170.3% |
| FY2014 | Dec 31, 2014 | $11.84M | +13.7% |
| FY2013 | Dec 31, 2013 | $10.42M | – |
| FY2012 | Dec 31, 2012 | -$2.37M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$119.51M | – |
| Q2 FY2026 | Jun 30, 2026 | -$122.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$111.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$109.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$95.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$93.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$72.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$76.81M | – |
| Q3 FY2024 | Sep 30, 2024 | -$73.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$68.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$58.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$54.32M | – |
| Q3 FY2023 | Sep 30, 2023 | -$53.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$55.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$48.70M | – |
| Q4 FY2022 | Dec 31, 2022 | -$43.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.39M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$479.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.93M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.68M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.04M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.44M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.66M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.90M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.48M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.72M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.82M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.30M | – |
See a number that looks wrong?